We previously reported an association between the functional polymorphism in the upstream regulatory region of the serotonin transporter gene (SERTPR) and the prophylactic efficacy of lithium in a sample of 201 Italian subjects affected by Mood disorders. The aim of the present study was to replicate analyses on an independent sample. In total, 83 subjects affected by Bipolar disorder were recruited in the Mood Disorders
INTRODUCTION
Lithium is an effective prophylactic agent in mood disorders but not all patients equally respond to lithium therapy. Clinical predictors account for less than half of the variance, [1] [2] [3] [4] [5] [6] [7] [8] and there are evidences suggesting that genetic factors play a substantial role in lithium prophylaxis effectiveness. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] A large number of studies reported an association between prophylactic lithium response and a family history of bipolar disorder, 10, [12] [13] [14] 17 although not unequivocally confirmed. [21] [22] [23] [24] [25] Recently, Grof et al 26 reported that lithium response in a sample of relatives of responder probands was 67% compared to 30% in the comparison group.
The mode of action of lithium salts used in the prophylaxis of affective disorders is still unknown. Previous studies [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] evidenced lithium effects on serotonine (5-HT) function at the levels of precursor uptake, synthesis, storage, catabolism, release, receptors and receptor-effector interactions. These actions of lithium may serve to correct 5-HT function abnormalities involved in the pathogenesis of mood disorders. 38 However, this view is not univocally accepted because others suggested that the effects of lithium on synaptic transmission and on neuronal excitability appeared independent of changes in endogenous 5-HT. [39] [40] [41] [42] The serotonin transporter is the major determinant of serotonin inactivation following release at synapses and it is the site of action of most antidepressants. The gene coding for it has been proposed as a possible candidate for involvement in the pathogenesis of major psychoses. A functional polymorphism in the upstream regulatory region of the gene has been associated with both major depressive and bipolar disorders, [43] [44] [45] although subsequent studies did not replicate these results. [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] The polymorphism in the upstream is a deletion/insertion (SERTPR) located exactly at the 5 0 -flanking regulatory region of serotonin transporter gene on chromosome 17q11.2. It consists of a 44-bp insertion or deletion involving repeat elements 6 to 8 (from bp À1212 to bp À1255). 59 In a previous work, 60 we found SERTPR variants associated with lithium outcome (P ¼ 0.005) in a sample of 201 patients consecutively admitted to the Lithium Clinic for Mood Disorders of S Raffaele Hospital in Milan. Subjects with the s/ s variant showed a worse response compared to both l/s and l/l variants. Interestingly, our results on lithium efficacy were consistent with the observation of a reduced efficacy of antidepressant treatment in subjects with the SERTRP short variant. 61 The only other report was by Del Zompo et al, 62 who found a trend of long allele for higher frequency among lithium nonresponders compared to controls. The aim of the present work was to replicate analysis on an independent sample from the Mood Disorders Clinic of the Eginition Hospital of the Athens University, Medical School Department of Psychiatry. Lithium dosages were adjusted to obtain plasma levels in the range of 0.65-0.75 mMol/l. In the overall sample, lithium dosages ranged between 300 and 1800 mg/die and the mean dosage was 11737244 mg/die. The majority of patients received lithium at a dosage between 900 and 1500 mg/die (n ¼ 80). A total of 24 subjects received lithium at a dosage lower than 1200 mg/die (300 mg/die: n ¼ 1; 600 mg/die: n ¼ 1; 900 mg/die: n ¼ 22), while 59 subjects were administered lithium at 1200 mg/die or higher (1200 mg/die: n ¼ 36; 1350 mg/die: n ¼ 7; 1500 mg/die: n ¼ 15; 1800 mg/die: n ¼ 1).
MATERIALS AND METHODS
All patients were observed prospectively for a follow-up period of 3 years after lithium administration with respect to their response to lithium treatment. Responders to lithium treatment were defined as those patients who did not develop any illness phase during the 3 years of lithium treatment. Those patients who developed an illness phase in the 3-year-period were routinely considered nonresponders; information regarding number and characteristics of illness episodes during lithium treatment was not collected. Patients who failed to attend the clinic during the followup period were excluded from the study.
Lifetime diagnoses were assigned by two independent psychiatrists on the basis of interviews and medical records, according to DSMIV criteria. 63 Information about the illness before contact with the Mood disorder clinic was collected following the best estimate procedure interviewing the subjects, family members, previous health professionals and obtaining records when possible. 64 The presence of concomitant diagnoses of mental retardation, drug dependence, or other Axis I disorders, together with somatic or neurological illnesses that impaired psychiatric evaluation, represented exclusion criteria. Probands were unrelated and of Greek descent, with antecedents of Greek ethnicity, from all parts of the country. At the intake, none, out of the 83, was affected by a thyroid disorder; 31 developed a thyroid illness during lithium treatment. Informed consent was obtained from participants after the study was explained. The study was carried out in accordance with the principles of the Declaration of Helsinki. 65 
DNA Analysis
Genomic DNA was extracted from leucocytes by NaCl precipitation. 66 PCR forward primer 5 0 -GGCGTTGCCGCT CTGAATGC-3 0 and reverse primer 5 0 -GAGGGACTGAGCTG GACAACCAC-3 0 were employed. In total, 35 cycles of 1 min at 951C, 1 min at 611C and 1 min at 721C were performed. The assay mix, in a volume of 30 ml, contained 50 ng genomic DNA, 2.5 mM dNTPs, 0.1 mg of sense and antisense primer, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 5% DMSO and 1 U Taq Polymerase. PCR products were separated on 3% agarose gel supplemented with ethidium bromide allowing differentiation of the long (528 bp) and the short (484 bp) variant.
Statistical Analysis
To investigate the possible association between SERTPR variants and response to lithium treatment, we used the w 2 test. Alpha levels were considered significant when less than 0.05. Variables considered as possible confounders were: sex, age, age at onset, diagnosis, number of total episodes before lithium administration, presence of psychotic features, thyroid disorders, mood stabilizer treatment, lithium dosages and response to lithium treatment. Possible associations were assessed using Analysis of Variance (ANOVA) for continuous variables and w 2 test for categorical variables. Logistic regression was performed to control possible confounders (sex, age, age at onset, diagnosis, number of total illness episodes, suicide attempts, psychosis, thyroid disorders).
The power of our sample to detect differences among SERTPR variants was calculated considering an alpha value of 5% two tailed, by the GPOWER programme, version 2.0. 67 With these parameters in our sample, we had a high power (0.80) to detect a medium effect size (w ¼ 0.31) that corresponded to a difference of approximately 30% between two major genotypes on response. 68 
RESULTS
In the present sample, SERTPR genotypes were in HardyWeinberg equilibrium (w 2 ¼ 2.0; df ¼ 1; P ¼ 0.2). SERPR long and short allele frequencies were, respectively, 0.51 and 0.49, similar to those of previously published samples in Caucasians 45, 59, 69, 70 and similar to those observed in our Italian sample (0.57 and 0.43, respectively). 60 Italian and Greek samples were not different in terms of SERTPR genotypes frequencies (w 2 ¼ 4.3; df ¼ 2; P ¼ 0.1). On the other hand, Asian frequencies were different from all Caucasian samples. 71, 72 Demographic and clinical features of the sample are described in Table 1 . We observed statistically significant excesses of the SERTPR*s/s genotype among psychotics, of the s/l genotypes among females and a trend for an excess of the l/l genotype among subjects with a younger age at onset. However, those variables were not associated with the response to lithium treatment.
Treatments, dosages and response to prophylactics therapies are described in Table 2 . Groups were not different with respect to stabilizing therapy they received (lithium or lithium plus other stabilizers), although a trend towards higher lithium dosages among subjects with the SERTPR*l/l genotype was observed.
SERTPR groups did not differ with respect to their response to lithium treatment; subanalyses by diagnosis (BP I, BP II) did not yield any significant association. However, when considering other subpopulations we found significant associations between SERTPR and lithium outcome. Those subpopulations were defined by the number of manic episodes experienced before lithium administration, and by lithium dosages they were administered too. An excess of the SERTPR*s/l genotype was observed among females; an excess the SERTPR*s/s genotype was observed among psychotics; and an excess of the l/l genotype was observed among subjects with a lower age at onset.
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In fact, in the present sample, the response to lithium treatment was negatively correlated with the number of previous manic episodes (R ¼ À0.3; P ¼ 0.02) and a trend for high lithium dosages among l/l SERTPR subjects was found (F ¼ 3.1; df ¼ 80; P ¼ 0.051). We hypothesized that previous illness pattern and dosages of lithium administered could affect the response to lithium treatment. Thus, to control these possible confounders, we grouped patients in terms of the bipolar illness pattern before lithium treatment and for dosages of lithium treatment.
As presented in Figure 1 , among subjects who experienced few manic episodes (p4) before lithium administration, those homozygotes for the long SERTPR allele were more likely to develop an affective episode during the 3-years period of follow-up. Conversely, SERTPR short allele-containing genotypes showed a higher incidence of responders (i.e. patients who did not develop an effective episode during the 3 years of lithium treatment). A similar trend was found among subjects with a higher daily dose of lithium (X1200 mg/die) (Figure 2) .
Both results were not influenced by the other clinical factors such as sex, age, age at onset, diagnosis, number of total illness episodes, suicide attempts, psychosis and thyroid disorders, except for a marginal decrease of significance for the association between SERTPR and response in the subgroup with higher lithium doses when including suicide attempts, psychosis and thyroid disorders in the logistic regression model.
DISCUSSION
Previous pharmacogenetic studies evidenced the involvement of some candidate genes on the response to lithium prophylactic treatment. Among those candidate genes, the tryptophan hydroxylase C allele (TPH), 73 the phospholipase C g-1 gene (PLCG1) repeat, 74, 75 the C973A polymorphism in the inositol polyphosphate 1-phosphatase 76 and the mitochondrial DNA (mtDNA) 10398 polymorphism, 77 have been suggested as being associated with positive lithium response.
We previously reported an association between the functional polymorphism in the upstream regulatory region of the serotonin transporter and lithium outcome. 60 The aim of the present work was to replicate the finding in an independent Greek sample. 1 SERTPR genotypes and response to lithium treatment among subjects who experienced a lower number of manic episodes (np4) before lithium. The l/l SERTPR genotype was associated with a higher incidence of non-responders to lithium treatment (v 2 ¼ 7.7; df ¼ 2; P ¼ 0.02). The l/l SERTPR genotype was significantly associated with a higher incidence of nonresponders to lithium treatment, compared to short allele-containing genotypes, taken together (v 2 ¼ 7.7; df ¼ 1; P ¼ 0.005). SERTPR genotypes were not associated with response to lithium treatment. A trend for a lower lithium dosage was observed among subjects with the s/l genotype.
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In the present sample, we found that homozygosity for the long SERTPR gene was associated with a higher probability of developing an affective episode into 3 years of lithium treatment. This was statistically significant among subjects who experienced few manic episodes (p4) before lithium administration and among subjects who received a high lithium daily dose (X1200 mg/die). No differences were observed between Bipolar disorder subdiagnoses (BP I, BP II). However, in the whole sample we could observe only a trend towards a poorer response to lithium treatment among subjects carrying the l/l SERTPR genotype. Confounding factors, such as sex, age, age at onset, diagnosis, number of total illness episodes, suicide attempts, psychosis and thyroid disorders, did not affect response to lithium treatment and the observed association.
These results suggest that the relation between SERTPR gene and the response to lithium treatment may also be affected by the natural history of the illness, together with the individual's capacity to retain lithium. In fact, differences among SERTPR genotypes emerged only among those subjects who experienced few previous manic episodes and among those subjects who received high doses of lithium. Since the dosages of lithium were adjusted to obtain adequate plasma levels, subjects who received high lithium dosages may have a low capacity to retain lithium. In fact, in the present sample, l/l SERTPR subjects, the ones with a poorer lithium efficacy, also showed a trend for higher lithium dosages, compared to other subjects. Those subjects may therefore benefit less from lithium. We may hypothesize that both illness recurrence and lithium retaining capacity could be affected in a complex interaction by the SERTPR genotype. Moreover, although in the present sample the SERTPR genotype was not associated with the illness time course (data not shown), we previously reported that l/l SERTPR subjects have a higher illness recurrence independent of lithium administration, as compared to subjects carrying other genotypes. 60, 78 However, the total number of episodes was not a significant stratification factor and we should admit that our methodology was not aimed to investigate this issue properly.
Overall, data on the present sample did not confirm our previous finding of a worse outcome of lithium treatment among subjects carrying the s/s SERTPR genotype. 60 In fact, Greek nonresponders were more likely to be homozygotes for the long SERTPR allele. A similar association between SERTPR*l/l genotype and a poor response to lithium prophylactic therapy was also reported by Zompo et al. 62 However, our previous study and the present one were different with respect to the definition of 'lithium outcome'. Previously, 60 we estimated lithium efficacy in terms of modification of the illness recurrence, by calculating the difference between the pre-and the on-lithium treatment recurrence rates (continuous evaluation of the outcome). 79, 80 In the Greek sample, the lithium treatment effectiveness was judged by the absolute absence of recurrences in the 3 years of observation, independent of the previous illness pattern (categorical evaluation of the outcome).
Results on heterozygotes subjects were instead similar in the two samples. In the Italian sample, we observed a significant reduction of episodes after lithium administration among subjects carrying the SERTPR*s/l genotype. Accordingly, in the Greek sample, s/l SERTPR genotype was associated with a better response to lithium treatment (absence of illness episodes during lithium). Finally, another reason for the conflicting results could be due to the fact that the polymorphism investigated is in linkage disequilibrium with a nearby functional one. 81 Recently, the SERTPR polymorphism has been associated with the antidepressant response to certain selective serotonin reuptake inhibitors, such as fluvoxamine [82] [83] [84] [85] and paroxetine. 86, 87 A possible common mechanism may therefore underlie SSRI and lithium efficacy even if the exact mechanism of action of lithium activity is largely unknown.
A limitation of the present study is that a number of clinical variables were not considered, such as number of days of hospitalization, the recurrence rates during lithium treatment, the episodes' sequence type (depression/mania), 4 the severity of depressive and manic episodes, subthreshold symptomatology, 88 life events, time course after lithium nonresponse or the time course of plasma lithium levels. Moreover, the sample size did not have the ability to detect small differences, as shown by the power analysis.
Considering these limitations, and the possibility of falsepositive findings, the present study supports a possible association between the SERTPR gene and lithium efficacy among patients affected by Bipolar disorders. However, the present data conflict with previous findings; thus further studies on independent and large samples are required to establish the reliability and the direction of a possible association between SERTPR variants and lithium outcome.
